Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04886934
Other study ID # 2020-004776-17
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date October 25, 2021
Est. completion date March 2025

Study information

Verified date January 2024
Source Cardiaccs AS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Transesophageal echocardiography is used to monitor cardiac wall motion at various time points during open-heart surgery. After surgery, the measurements are made at various time points by transthoracic echocardiography. The CS1 system enables continuous, direct measurement of cardiac wall motion. This is achieved through use of temporary pacemaker wires incorporating a motion detector called an accelerometer. Use of TMEs during and after open-heart surgery is part of the normal clinical routine. Continuous monitoring of cardiac wall motion during and after surgery can quickly highlight the need for medical intervention with cardiac drugs and allow very early detection of potentially serious complications leading to abnormal cardiac wall motion. Cardiac wall motion activity registered by the CS1 system and echocardiography at specific time points during and after surgery will be analyzed to see how well they compare.


Description:

Echocardiography is currently the most important and most widely used tool in cardiology besides electrocardiography (ECG). It is reliable for assessing all stages of cardiovascular disease, and it is commonly used to detect heart (cardiac) wall motion dysfunction during and after open-heart surgery. During open-heart surgery, transesophageal echocardiography (when the echocardiography sensor is introduced into the esophagus) is used to monitor cardiac wall motion at various time points during surgery. After surgery, the measurements are made at various time points by transthoracic echocardiography (when the echocardiography sensor is placed on the chest wall). Use of the CS1 system enables continuous, direct measurements of cardiac wall motion. This is achieved through use of temporary pacemaker wires (also called temporary myocardial electrodes or TMEs) incorporating a motion detector called an accelerometer. Use of TMEs during and after open-heart surgery is part of the normal clinical routine. Continuous monitoring of cardiac wall motion during the surgery and the post-surgical recovery period can, for example, quickly highlight the need for medical intervention with cardiac drugs and allow very early detection of potentially serious complications such as ischemia (heart muscle is not receiving enough oxygen) and myocardial dysfunction (cardiac wall motion appears abnormal). The key feature of the CS1 system is that the cardiac wall motion activity registered by the novel TMEs incorporating the accelerometer are displayed visually on a standard medical monitor and synchronized with the patient's ECG data. These data can easily be viewed by medical staff to check if the patient's condition is satisfactory or whether medical intervention is needed. In the study, the CS1 system will be used in addition to the standard monitoring procedures that include ECG, blood pressures and intermittent echocardiography. Cardiac wall motion activity registered by the CS1 system and echocardiography at specific time points during and after surgery will be analyzed to see how well they compare.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 38
Est. completion date March 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years to 99 Years
Eligibility Inclusion Criteria: 1. Patients with heart disease requiring surgery 2. Above 18 years 3. Patients suitable for study participation without safety concerns based on the Investigator's evaluation of medical history and physical examination. 4. The patient must be able to understand the aims and objectives of the trial, willing and able to comply with all study related procedures 5. The patient must be willing and able to provide written informed consent prior to participation in the clinical investigation 6. The patient agrees to abstain from enrollment in any other clinical investigation for the duration of the study Exclusion Criteria: 1. Esophageal disease 2. Atrial fibrillation 3. Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CS1 System
Placement of CS1, a temporary bipolar myocardial electrode (TME) with an integrated motion sensor (accelerometer), on the left ventricle and externalization of the associated leads through the chest wall during open-heart surgery. CS1 will remain in place for up to 7 days after surgery and closure of the chest wall.

Locations

Country Name City State
Norway Oslo University Hospital Oslo

Sponsors (2)

Lead Sponsor Collaborator
Cardiaccs AS European Commission

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Peak Systolic Velocity (PSV) after increasing heart rate by 25 percent Correlation between relative changes in PSVs measured by CS1 and echocardiography After surgery: before extubation, while patient is in the intensive care unit (ICU)
Primary Change from Baseline PSV after increasing heart rate by 25 percent Correlation between relative changes in PSVs measured by CS1 and echocardiography After surgery: after extubation and removal of drains, before patient is transferred from ICU to general ward
Secondary Adverse Events Incidence of non-serious and serious adverse events rated for causality Up to 30 days after surgery
Secondary Adverse Device Effects Incidence of non-serious and serious adverse device-related effects Up to removal of device at a maximum of 7 days after surgery
Secondary Device Deficiencies Incidence of device deficiencies Up to removal of device at a maximum of 7 days after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05490303 - HeartGuide: Preliminary Study N/A
Completed NCT05070819 - Atrial Natriuretic Peptide in Assessing Fluid Status N/A
Not yet recruiting NCT04511403 - Prevalence of Oral Mucosal Alterations In a Sample of Egyptian Patients With Cardiovascular Diseases: A Hospital- Based Cross-Sectional Study
Not yet recruiting NCT04538469 - Absent Visitors: The Wider Implications of COVID-19 on Non-COVID Cardiothoracic ICU Patients, Relatives and Staff
Completed NCT02697760 - The CZT Dynamic Myocardial Perfusion Imaging
Terminated NCT05157568 - Pilot Randomized Clinical Trial of Live-streamed Cardiovascular Rehabilitation N/A
Not yet recruiting NCT04160845 - Non-invasive Forehead Skin Temperature in Cardiac Surgery
Completed NCT04500912 - Comparison of the Supraflex Cruz 60 Micron Versus the Ultimaster Tansei 80 Micron in HBR PCI Population N/A
Not yet recruiting NCT06438159 - Impact of Mindfulness-Based Stress Reduction Meditation Practice on Patients After Cardiac Rehabilitation. N/A
Recruiting NCT06154473 - Assessment of Patients Undergoing Cardiac Surgery and Admitted to the Intensive Care Unit
Not yet recruiting NCT05877755 - Validation of Multi-contrast, High-resolution Cardiac Magnetic Resonance Imaging N/A
Completed NCT03394859 - Electronic Medical Records and Genomics (eMERGE) Phase III
Recruiting NCT05055830 - Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)
Recruiting NCT04374799 - Heparin vs Placebo for Cardiac Catheterization Phase 3
Completed NCT03174106 - Longterm Follow-up of Cardiac Patients With an Smartphone-Application N/A
Recruiting NCT05531253 - Respired Gases in Patients Post Cardiac Surgery
Recruiting NCT04609228 - Cardiac Surgery Outcomes in Blood-transfusion Acceptors and no Acceptors
Recruiting NCT06149143 - Cardiac Performance System Data Collection Study - Minnesota
Recruiting NCT05725655 - Hot Water Immersion After Myocardial Infarction N/A
Recruiting NCT06073509 - Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRT